Latest Synthetic Biologics Inc. Stories
-- First-in-Class Clinical Program Targets Protection of Microbiome to Prevent Overgrowth of Deadly C. difficile Infection Linked with Use of IV Antibiotics -- ROCKVILLE, Md., Dec.
-- Phase 1a and 1b Trials to Use SYN-004 to Protect Microbiome; Intended to Prevent Overgrowth of Potentially Deadly C. difficile Bacteria -- ROCKVILLE, Md., Nov.
-- Mark Pimentel, M.D., FRCP(C), of Cedars-Sinai Medical Center Serves as Chairman -- ROCKVILLE, Md., Oct.
ROCKVILLE, Md., Oct.
-- Mark Pimentel, M.D., of Cedars-Sinai Delivered Keynote Presentation on Mechanism of Action -- ROCKVILLE, Md., Sept.
-- Company Expects to File IND to Support Clinical Trials in Mid-2015 -- ROCKVILLE, Md., Sept.
-- Conference Call Scheduled for Friday, September 12, 2014, at 9:15 a.m. EDT -- ROCKVILLE, Md., Sept.
-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board --
-- SYN-005 Neutralizing Antibody Combination Protects Against Pertussis in Murine and Non-Human Primate Models -- ROCKVILLE, Md., Sept.
ROCKVILLE, Md., Sept.